Prof. Ruibao Liu 刘瑞宝
Chief Physician, Professor
Department of Interventional Radiology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis and comprehensive treatment of liver cancer, including interventional therapy, ablation, targeted drugs, and immunotherapy. Lung cancer particle therapy. Stent placement for bile duct, esophageal, and tracheal conditions.
Dr. Liu is Director of the Interventional Department at Harbin Medical University Cancer Hospital and holds a medical doctorate. Since starting work in 1986, Dr. Liu became Heilongjiang Province’s first interventional specialist with a doctorate in 2003. An expert contributor to China’s Primary Liver Cancer Diagnosis and Treatment Norms (2017, 2019 editions), Dr. Liu trained at UPMC and BCLC.
Professional roles
- Member, Interventional Professional Committee, Chinese Society of Radiology
- Standing Committee Member, Tumor Intervention Professional Committee, China Anti-Cancer Association
- Chair, Tumor Intervention Branch, Heilongjiang Medical Association
- Editorial Board Member, Journal of Interventional Radiology
Name order: in Chinese the family name comes first (Liu Ruibao). Papers usually list the name as Ruibao Liu or Liu R.
Selected publications
20 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Medicine (Baltimore), 2026 (senior author): Prediction of postoperative mortality risk in hepatocellular carcinoma based on biomarkers and neural network models. PubMed 42152385
- J Hepatocell Carcinoma, 2025 (senior author): TACE-HAIC Plus Targeted Therapy and Immunotherapy for HCC with Tumor Thrombus and Arteriovenous Fistula. PubMed 41467098
- Front Oncol, 2025 (senior author): Efficacy and safety of TACE-HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for the patients with BCLC-defined stage B-C HCC. PubMed 40799236
- Oncol Lett, 2025 (senior author): Efficacy of transarterial chemoembolization-hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. PubMed 40469916
- BMC Med Genomics, 2025 (senior author): Targeting RECQL4 in hepatocellular carcinoma: from prognosis to therapeutic potential. PubMed 40001159
- Transl Oncol, 2024 (senior author): CREB3 facilitates Donafenib resistance in hepatocellular carcinoma cells via the LSD1/CoREST/p65 axis by transcriptionally activating long noncoding RNA ZFAS1. PubMed 38641372
- Acta Biochim Biophys Sin (Shanghai), 2020 (senior author): NACC-1 regulates hepatocellular carcinoma cell malignancy and is targeted by miR-760. PubMed 32091103
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion